-
WNBA, players union agree 'transformative' labor deal: official
-
US Fed holds rates unchanged over 'uncertain' Iran war implications
-
Senegal govt calls for investigation into Cup of Nations decision
-
From Faraja to Sepah: Iran's multiple security forces
-
Billionaire Dyson buys 50 percent stake in Bath rugby
-
Senegal demands 'corruption' probe over AFCON decision as Morocco defend appeal
-
The platypus is even weirder than thought, scientists discover
-
PSG's Barcola ruled out for several weeks with ankle injury
-
Colombia detains suspect in 2023 killing of Ecuador politician
-
Iran condemned as UN maritime body holds emergency talks on Mideast shipping
-
Iraqi Kurdish shepherds stoic in face of yet another war
-
Iran women's football team return after asylum tussle
-
US launches new era of drug war with Latin American allies
-
How many cargo ships are passing Hormuz strait?
-
'Free France': Macron reveals name of Europe's largest warship
-
Oil surges as Iran gas facilities hit, stocks slide
-
Foreign press group slams Israeli police for breaking journalist's wrist
-
McIlroy happy with back injury recovery as Masters looms
-
Vinicius 'should be loved by everyone' says Donnarumma after celebration row
-
Iran was not rebuilding nuclear enrichment, US intelligence finds
-
Carrick urges England boss Tuchel to call up United trio
-
Three sporting champions to be stripped of titles for non-doping reasons
-
Chilean GDP beats 2025 forecast despite mining dip
-
Storms, warm seas drove sudden drop in Antarctic ice: study
-
Aston Villa want to be more than a 'maybe team' in quest for Europa League
-
Trump administration takes steps to curb energy cost hikes
-
Vaccines facing misinformation spike: WHO experts
-
Pakistan announces Eid 'pause' in conflict with Afghanistan
-
'Happened so fast': UK students panicked by meningitis outbreak
-
WNBA, players union agree 'transformative' labor deal: reports
-
Global music market grows, calls for AI compensation: industry body
-
Maiduguri bombings follow surge of jihadist violence in Nigeria
-
Belgian court suspends TotalEnergies climate trial
-
Troubled waters: Thai fishermen marooned by rising fuel costs
-
Doku adamant Man City still have plenty to play for after Champions League exit
-
Afghanistan vows to avenge deadly Kabul bombing but says open to talks
-
Nigerian president meets royals on 'historic' UK state visit
-
South Lebanon residents flee death and destruction
-
Buttler ready to continue England career despite 'poor' T20 World Cup
-
Why convoys cannot fully protect oil tankers from Iran attacks
-
UK PM leads efforts to halt deadly meningitis spread
-
EU lawmakers back ban on sexualised AI deepfakes
-
Stripping Senegal of AFCON title a 'disgrace for Africa' say fans
-
Under Hezbollah fire, people in north Israel hope for better days
-
Iran women's football team cross Turkish border to head home: AFP
-
Fear in central Beirut as Israel strikes, with and without warning
-
'France is wild': Macron to unveil name of Europe's largest warship
-
Arsenal's Trossard says Leverkusen win ideal ahead of League Cup final
-
Israel conducts wave of strikes on Beirut
-
Seven-year term sought for Norway princess's son for alleged rapes
Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
G.Stevens--AMWN